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Abstract:   Compression therapy remains the only treatment option for venous ulcers with <100%  success.  A  better  understanding  of  the mechanisms  regulating  venous ulcer healing might give rise to better treatments.  
Urokinsae  plasminogen  activator  receptor  (uPAR),  a  GPI  anchored  3‐domain protein exists either attached to cell wall or in soluble forms (suPARI‐III, suPARI &  suPARII‐III  fragments).  Cleavage  of  uPAR  results  in  a  number  of  non‐proteolytic functions that may be important in wound healing.  Our aim was to determine whether suPAR and its fragments are present in the environment of venous ulcers and whether this receptor has a role in ulcer‐healing.  
Ulcer  exudates  and  ulcer  tissue  biopsies  were  obtained  from  patients  with confirmed  venous  leg  ulcers.  Venous  ulcers  that  healed  within  6months  of compression therapy were classified as healers (H) while those that did not heal in  this  time  were  defined  as  non‐healers  (NH).  Time  resolved  fluorescence immunoassays (TR‐FIA) were validated  for measurement of suPAR  fragments. TR‐FIAs specifically detected their antigens in wound exudates, but not in tissue homogenates. All forms of suPAR fragments were detected within venous ulcer exudates. Levels of all 3 suPAR fragments were significantly higher in exudates obtained  from  H  compared  to  NH.  ELISA  analysis  of  uPA  and  plasminogen acitvator  inhibitor  (PAI‐1)  antigen  revealed  that  levels  were  similar  in  ulcer exudates and tissue homogenates from H and NH. 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1.1 Definition and historical background of venous ulceration Ulceration  is a  loss of epithelial  lining of an organ. When ulceration occurs on the  lower  limb  skin  secondary  to  an  underlying  venous  pathology  it  can  be defined as a venous  leg ulcer. Venous ulcers are commonly seen on  the  lower medial aspect of leg also known as the gaiter area. 






Venous stasis     Homans in 1917, was the first to describe stagnant blood as a cause of hypoxia leading to ulceration[5]. He suggested that patients with  ineffective  deep  vein  valves  would  have  a  “stagnant”  column  of  blood leading to lack of nutrition and tissue hypoxia leading to ulceration. The theory of venous stasis was nullified by the work done by Blalock, who showed a higer oxygen concentration in blood obtained from patients with venous ulcers[6, 7].  
Arteriovenous shunting   The  confirmation  of  higher  oxygen  content  in venous  blood  of  lower  limbs  from patients with  venous  ulcers  stimulated  the theory  of  “arteriovenous  shunting”.  Shunting  of  blood  in  ulcerated  limbs was first suggested by Holling et al in 1938, but Pratt in 1949 was the first to suggest the  presence  of  arteriovenous  shunts  beneath  the  lower  limb  skin  in  patients with venous ulcers[2, 8].  In 1953 Piulacks and Vidal Barraquer supported this theory by showing a higher oxygen content and faster circulation time in limbs of  patients  with  venous  insufficiency.  According  to  this  theory  artriovenous shunts lead to anaemic anoxia leading to ulceration of lower limbs. The findings of a study using microspheres suggests that there are no pathological shunts in patients  with  venous  ulcers  and  therefore  demolished  the  theory  of arteriovenous shunts[9]. 
The fibrin cuff    In  1982  Browse  and  Burnand  postulated  the  fibrin  cuff theory[6]. They suggested the extravasation of fibrinogen from the capillaries as a result of high venous pressure followed by polymerisation of  fibrinogen into insoluble  fibrin.  The  initial  work  done  for  this  hypothesis  showed  increase 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capillary  permeability  and  escape  of  fibrinogen  after  eleveation  of  venous pressure  in  the  hind  limb  of  a  dog.  It  was  further  postulated  that  due  to  the inadequate fibrinolytic activity, the fibrin deposited around capillaries resulted in  a barrier  to oxygen and other nutrients  to  the  skin. This was  supported by studies that showed histological  finidings of  fibrin cuffs[10]. The first question about  the  validity  of  this  theory  was  raised  by  the  same  group  when  a randomized  controlled  trial  using  oral  stanozolol  (a  profibrinolytic  agent)  did not  result  in better healing of venous ulcers[11].  In another study use of  local fibrinolytic  agent  tPA  also  failed  to  dissolved  the  pericapillary  fibrin[12].  The fibrin cuff  theory has  therefore  lead  to  the confirmation of pericapillary  fibrin deposition but the role of these fibrin cuffs in leading to ulceration could not be proven 
White cell trapping    According to this theory, propsed by the Middlesex group, white cells, which are larger than red blood cells, can block the capillaries resulting  in decreased capillary perfusion pressure.  Increased accumulation of white  cells  during  prolonged  venous  stasis  may  therefore  lead  to  local ischaemia  leading  to  ulceration[13]  [14].  These  trapped  white  cells  can  also release  toxic  metabolites  resulting  in  capillary  damage  and  increased permeability  for  larger macromolecules  like  fibrin. Further  studies attempting to prove this hypothesis failed to demonstrate capillary occlusion by white cells and  therefore  could  not  link  hypoxia  with  occlusion  of  capillaries  by  white cells[15]. 
Growth factor trapping  Another  theory  about  the  cause  of  venous ulceration was proposed by Falanga. This theory of venous ulceration proposes 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that  leaked  macromolecules  e.g.  fibrin  and  α2  marcoglobulins  trap  growth factors  that are required  for  tissue  integrity and repair[16].  Just  like  the other theories,  it  is difficult to prove the cause and effect relationship of the trapped growth factors and venous ulceration [16‐18] 
These  uproven  theories  about  venous  ulcercation  demonstrate  our  lack  of knowledge  about  mechanisms  leading  to  venous  ulceration.  This  limited knowledge is reflected on the lack of efficacious treatments options other than compression bandaging that is currently the mainstay of ulcer treatment. 
 
1.3 Epidemiology and impact on population About 1% of all adults will suffer from leg ulceration at some stage in their life with venous leg ulcers accounting for >70% of these ulcers[19]. In the latest and first global epidemiological study (The Vein Consult Program) the incidence of relatively  less  severe  form of  chronic  venous  disease  (CEAP  class  C1‐C3) was higher  in  females except  for CEAP class C0  that was more prevalent  in males. The more  severe  form  of  disease  (C4‐C6) was  equal  between  the  two  gender groups[20]. 
The cost to treat venous disease (ranging from oedema to active ulcers)  in UK was calculated to be >£600 million per year in 1992[21]. In addition to the cost of treating venous ulcers, there is also a high impact on quality of life as a result of  pain  and  disability.  Compression  therapy  is  the  main  treatment  for  these ulcers  and  results  in  70‐80%  healing  within  6  months[22,  23].  If  curative treatment  is  not  undertaken  re‐ulceration  remains  a major  problem with  25‐55% of patients having recurrence of ulcers within 2 years[19, 24]. 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aided by  the calf pump and  functional valves assists  in decreasing  the pressure 
and blood volume upon walking. 
 
1.4.1 Calf pump failure Muscle groups in the foot, calf and thigh all act as pumps to aid venous return, but  the  most  important  and  efficient  is  the  calf  pump,  which  generates pressures  of  up  to  200mm  Hg  during  contraction[25].  Structured  exercise strengthens the calf pump and improves venous haemodynamics[26]. Failure of the calf muscles  to pump the venous blood against gravity  is a major cause of ambulatory venous hypertension.   The calf pump can fail as a result of muscle weakness  from disuse atrophy  that  is  commonly  seen  in  elderly patients. Any major  injury  to  the  calf  muscle  or  a  neurological  disease  e.g.  motor  neuron disease  can  result  in  calf  pump  failure.  Joint pathology  e.g.  arthritis  especially effecting the ankle joint will also lead to an impaired calf pump 
(Fig 8). Similar pressure changes are observed with
standing ankle plantar flexion or heel raising, transferring
weight to the forefoot (the tip-toe maneuver).18,27 Am-
bulatory venous pressure (AVP) can be determined using
a 21-gauge needle to measure the response to 10 tiptoe
movements, usually at a rate of 1 per second, in a dorsal
foot vein. When resuming a static standing position,
hydrostatic pressure is restored after a mean of 31 sec-
onds (Fig 8). Th incidence of ulceration has a linear
relationship to increases in AVP above 30 mm Hg. An
increased AVP is also associated with a 90% venous refill
time of !20 seconds.27
In contrast to the AVP, volume changes can be mea-
sured non-invasively using plethysmography. Rapid reflux
(ie, venous filling of greater than 7 ml/sec) and calf pump
dysfunction are associated with a high incidence of ulcer-
ation.16,26 Various authors have described the volume
changes associated with elastic compression, surgical inter-
vention, CEAP clinical class, avalvulia, diminished joint
function, and late day deterioration of venous func-
tion.16,21,23,26,28 The interrelationship between pressure
and volume is summarized schematically in Fig 8.
PATHOPHYSIOLOGY OF CHRONIC VENOUS
INSUFFICIENCY
Chronic venous insufficiency defines those manifesta-
tions of venous disease resulting from ambulatory venous
hypertension, defined as a failure to reduce venous pressure
with exercise. Under nor al circumstances, the v nous
valves and the muscular pumps of the lower extremity limit
the accumulation of blood in the lower extremity veins.
Failure of the lower extremity muscle pumps due to out-
flow obstruction, musculo-fascial weakness, loss of joint
motion, or valvular failure is associated with peripheral
venous insufficiency.16,23,27 However, an efficient periph-
eral pump m y compensate for some degree of reflux and
obstruction and prevent symptoms of chronic venous in-
sufficiency (CVI).23,28
Determinants of ambulatory venous pressure include
venous reflux and obstruction as well as calf muscle pump
function.29,30 Valvular incompetence is associated with a
rapid recovery time after muscular contraction. If the deep
vei valves are incompet nt, blood si ply oscillates within
the deep veins and there is no reduction in pressure. Deep
Fig 8. The pressure and volume changes with activation of the calf muscle pump are demonstrated. Beginning in the
standing posture, the hydrostatic pressure baseline is demonstrated in a dependent, but non-weight bearing limb. The
subject then performs 10 tip-toe (heel-raising) maneuvers and resumes the non-weight bearing posture. A, This
schematic compares the pressure and volume changes along a concomitant timeline. Note the efficiency of the calf
pump in rapidly reducing either volume or pressure upon commencement of muscle activity. Although volume filling
begins within 5 to 7 seconds, pressure does not rise substantially for 30 to 40 seconds. Alterations in these relationships
can generate chronic, sustained venous pressure elevations, the end products of which are the symptoms and findings
of chronic venous insufficiency. B, Pressure changes during these maneuvers are illustrated in this recording from
cannulation of a dorsal foot vein reported in mmHg.C, Volume changes during these maneuvers are illustrated in this
air plethysmographic examination. The volume remaining in the limb after exercise divided by the venous volume
standing still is reported as the residual volume fraction (RVF, %).
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1.4.2 Incompetent venous valves Valves exist in both the superficial and deep venous systems, in addition to the junctions  between  the  two  systems.  Incompetent  valves  at  the  junction  of superficial and deep veins (sapheno‐femoral junction:SFJ and sapheno‐popliteal juction;SPJ)  result  in  blood  flowing  against  the  normal  pattern  of  flow  (i.e. superficial  to deep). This  results  in  transmission of high venous pressure  into the  superficial  veins.  The  exact  mechanisms  leading  to  valvular  dysfunction remain unclear. Incompetent venous valves along with weak dilated vein walls are  seen  in patients with CVI[27]. Recent  evidence  suggests weakening of  the vein  wall  to  be  the  initial  pathology  [27,  28].  As  the  weakness  progresses towards  the  valves  it  renders  them  incompetent.  The  weakening  and subsequent  dilatation  of  the  vein  wall  has  been  related  to  abnormal  elastin metabolism[29] and dysregulation of collagen synthesis[30]. 
There is now evidence to suggest a strong genetic association in primary valve failure.  Normal  development  of  venous  and  lymphatic  valves  appears  to  be dependent on the FOXC2 gene as mutations in this gene have been implicated in the development of primary valve failure[31]   
 
1.4.3 Outflow obstruction Obstruction  to  the  venous  flow  in  the  deep  veins  can  also  result  in  venous hypertension  leading  to CVI. Most  common  form of outflow obstruction  is  the formation  of  a  thrombus within  the  deep  veins which  often  starts  in  the  calf 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veins[32]. Ulceration develops in 5% of patients after deep vein thrombosis[33], which  arises when  one  or more  of  the  triad  of  factors  ‐    reduced  blood  flow (stasis),  damage  to  the  vessel  wall,  and  hypercoagulability  are  present[34]. Thrombosis  in  the  deep  venous  system  can  result  in  valve  damage  (though valve damage may also be the initial cause of thrombosis) and development of post  thrombotic  syndrome[32],  which  is  defined  as  the  presence  of  chronic venous symptoms and/or signs resulting  from deep vein  thrombosis[35]. Post thrombotic syndrome can present with a variety of sings and symptoms ranging from leg swelling to ulceration[36].  
 
1.5 Investigations to establish a venous cause of ulceration  In  order  to  look  for  causes  of  a  leg  ulcer  a  detailed  clinical  examination  is important. Once venous etiology is established the CEAP classification is helpful in  establishing  the  extent  of  venous  leg  pathology.  The  CEAP  (C‐clinical manifestation,  E‐etiological  factors,  A‐anatomic  distribution,  P‐pathophysiology) has been modified since its first introduction in 1994[37]. 
Investigations  that  confirm  the  findings of  clinical examination may start with the  use  of  hand  held  Doppler  that  can  be  performed  in  clinic.  Colour  duplex, plethysmography  and  venography  are  the  techniques  available  to  investigate the  venous  system  of  lower  limbs.  Duplex  scanning  is  sensitive  and  the most commonly  used  method  of  identifying  venous  pathology.  It  has  overtaken plethysmography  and  venography  as  it  is  non‐invasive,  relatively  quick  and inexpensive[38, 39]. A combination of duplex scanning and venous filling index 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(VFI)  obtained  by  air  plethysmography  is  considered  highly  sensitive  and specific[40]. Venography can be used to assess  the deep veins.  It  is warranted for  patients  who  have  an  unclear  diagnosis  or  in  whom  duplex  remains inconclusive.  
Improvement in ultrasound technology in the form of intravascular ultrasound has  shown  significantly  higher  sensitivity  when  compared  to  transfemoral venography  for  detection  of  iliac  vein  stenosis[41].  Improved  Computed tomography (CT) and Magnetic Resonance Imaging (MRI) has also enhanced the sensitivity to identify thrombosis in the deep venous system[39]. 
 
1.6 Treatment options Surgical  correction  of  the  underlying  pathology  has  been  shown  to  prevent recurrence  of  ulcers  but  combining  it  with  compression  bandaging  does  not improve  ulcer  healing[42].  The  main  treatment  for  venous  leg  ulcers  is compression bandaging. A variety of multi‐layered bandages are in use for the treatment  of  venous  ulcers.  The  amount  of  pressure  exerted  by  each  type  is different more so because of the subjective differences in the pressure applied when putting on the bandage. The most commonly used are the four‐layer and three‐layer paste regimen. The healing rate of ulcers is not influenced by the use of different layers of bandaging[43].  
In addition to compression bandaging a number of other treatments have been used  for  venous  leg  ulcers  but  none  of  them  on  their  own  have  shown  any significant  improvement  in  ulcer  healing.  These  include  use  of  platelet  rich fibrin  matrix[44],  ultrasound[45]  and  hyperbaric  oxygen[46,  47].  In  addition 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some  treatment  options  have  been  used  as  an  adjunct  to  compression bandaging.  These  include  electromagnetic  therapy[48],  electrical  therapy[49] and honey[50]. However the evidence for the use of these adjuncts is still weak and these are not generally used in practice. The pharmacological adjuncts used along  with  compression  therapy  have  shown  a  better  outcome  with  both pentoxifylline[51] and microinonized flavonoids[52] showing improved healing rates when used along with compression therapy. 
Once  ulcers  have  healed  a  number  of  interventions  can  be  undertaken  to address  the  underlying  pathology  and  thereby  prevent  recurrence.  A  brief description  of  the  treatments  that  may  be  used  to  treat  lower  limb  venous pathology in order to prevent venous ulcer recurrence is given below 
 
1.6.1 Compression stockings Compression stockings exert external pressure that  is greater at the ankle and then  reduces proximally.  In  cases where  surgical  correction of  the underlying pathology is not possible graduated compression stockings are the only solution to prevent ulcer recurrence.  It  improves the  function of  the venous pump[53]. The  compression  can  thereby  provide  relief  of  symptoms  and  improve  the venous  haemodynamics[54].  Patients  are  usually  given  Class  II  UK  standard compression  stockings  that  would  give  a  pressure  of  18‐24  mm  of  mercury. Other  types  of  class  II  stockings  (European & US)  give  a  different pressure. A compression  of  10‐30  mm  of  Hg  is  considered  to  be  effective  for  the management of symptomatic varicose veins, whereas compression of 30‐40 mm of  Hg  is  effective  for  healing  ulcers  and  preventing  progression  of  post 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thrombotic syndrome[55, 56]. The above knee stockings provide no advantage over  the  below  knee  stockings  for  prevention  of  recurrence[57].  The  level  of patient  compliance  with  the  compression  stockings  especially  during  hot weather is often not satisfactory. 
1.6.2 Treatment for superficial venous system pathology A  simplified  chart  of  the  available  treatment  options  for  superficial  venous system pathology is shown in Fig 2. 
 
Fig 2: Flow chart  for  the  treatments  that may be used  to  treat reflux within  the 
superficial  venous  system.  V­ACT:  Valvuloplasty  with  Axial  transposition  of 




Prior to the currently available endovenous techniques the standard treatment for  varicose  veins was  junctional  ligation  (SFJ  or  SPJ)  ±  stripping  of  the  vein (LSV or SSV) ± stab avulsions of varicosities.  
In cryostripping the only difference is that after ligation of the SFJ instead of a plastic stripper a metallic cryoprobe is passed down to LSV. The LSV is frozen at a temperature of – 85 °C (expansion of liquid nitrogen oxide in the cryoprobe) and  then  stripped.  A  RCT  showed  inferior  results  of  cryostripping  compared with  conventional  surgery  with  significantly  higher  residual  LSV  in  the cryostripping group[58].  
Surgery  specifically  aimed  to  correct  the  haemodynamic  abnormality  due  to incompetent  perforators  includes  subfacial  endoscopic  perforator  surgery (SEPS).  The  use  of  SEPS  has  not  shown  any  significant  improvement  in  the quality  of  life  or  ulcer  recurrence  when  compared  with  standard  LSV stirpping[59, 60].  
A  desire  to  spare  the  LSV  resulted  in  the  development  of  techniques  such  as axial  transposition  of  competent  tributary  (V‐ACT).  In  V‐ACT  valve  cusps  are repaired from outside the vein wall followed by transposition of pre‐operatively identified competent vein tributary[61]. Difficult learning curve and a strict pre‐operative  patient  selection  (having  repairable  valves)  limited  the  use  of  this technique.  
Amongst  the  more  popular  treatment  options  for  the  treatment  of  varicose veins is the endovenous thermal ablation that includes radiofrequency ablation 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(RFA) and endovenous laser ablation (EVLA). Both techniques are less invasive and have been shown to be as effective as open surgery[62].  






 Patients  with  post  thrombotic  syndrome  or  deep  venous  valve  incompetence are  only  considered  for  surgical  treatments  once  non‐invasive  methods (compression  therapy)  have  failed.  Even  then  surgical  corrections  of  deep venous  incompetence  are  only  undertaken  at  specialist  centers.  Techniques include  internal  valvuloplasty  (where  the  valve  is  repaired  after  making  a longitudinal  incision  over  the  vein)[64‐66],  external  valvulopasty  (where sutures  are  placed  externally)[66]  and  angioscopic  repair  (where  the transluminal repair is made after passing an angioscope into the vein)[66, 67]. The  use  of  external  valves  (VenocuffTM)  for  the  SFJ  has  reported  a  90% competence of SFJ at 44 months[68]. This procedure however  is only  suitable for  mild  varicose  veins  and  due  to  its  strict  preoperative  selection  criteria  it 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never  gained  popularity.  Choice  of  technique,  valve  reconstruction  in  post thrombotic  limbs  and  multiple  valve  reconstructions  remain  areas  of controversy in the field of deep vein valvuloplasty[66] 
In cases where valve repair  is not possible (e.g.  in post  thrombotic syndrome) artificial  venous  valves[69]  and  segmental  venous  transposition  has  been used[70].  Improvement  in  endovascular  techniques  has  allowed  use  of  stents for occluded iliofemoral veins. Raju et al reported a case series where stenting in  38  limbs with  iliofemoral  occlusion  showed primary  patency  of  49% at  24 months with 70% of patients having complete pain relief[71] 
 
1.7 Pathophysiology of normal wound healing  Non‐healing venous ulcers are types of wounds with an arrested healing process.  Understanding normal wound healing helps in assessing the pathological processes that may be contributing towards a non‐healing venous ulceration. 
Wound healing  is a complex process that can be divided  into different phases: hemostasis,  inflammation,  proliferation/re‐epithelialization  and  remodelling. However, none of the phases of wound healing is a distinct process and they are often  synchronously  merged  into  each  other,  with  the  same  wound  going through more  than one phase  at  one particular  time. At  the microscopic  level these  phases  are  represented  by  a  number  of  coordinated  cellular  and extracellular  processes  including  chemotaxis,  proteolysis,  proliferation, angiogenesis, cell migration and cell adhesion. 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The inflammatory phase starts with hemostasis and may last from 2 days to 2 weeks with neutrophils and macrophages being  the main orchestrators of  the inflammatory response. Platelet aggregation during this phase causes thrombin formation  leading  to  the  activation  of  the  fibrin  clot[72,  73].  Platelets  release various  growth  factors  and  inflammatory  mediators[74].  The  redness  and swelling  observed  at  the  time  of  injury  is  the  result  of  arterial  dilatation  and increased  vascular  permeability  secondary  to  the  release  of  histamine  from mast  cells[73].  Fibroblasts  that migrate  in  the wound  during  this  early  phase start  secreting  proteases  and  growth  factors[74].  After  the  initial  2‐3  days neutrophils are replaced by circulating monocytes which after embedding in the extracellular  matrix  (ECM)  differentiate  into  tissue  macrophages[75]. Monocytes/macrophages  play  a  vital  role  during  the  inflammatory  phase  as they  initiate  angiogenesis  and  formation  of  granulation  tissue  that  continues during the proliferative phase.  
Cells  involved  in  the  proliferative  phase  are  keratinocytes  and monocytes/macrophages  in  addition  to  fibroblasts.  The  ECM  takes  over  the central role during this stage leading to the formation of granulation tissue[73]. This  new  ECM  laid  down  primarily  by  fibroblasts[74],  consists  mainly  of collagen  type  III  and  fibronectin  and  is  crucial  for  the  progression  of  wound healing  as  it  allows  the  cells  to  interact with  each  other  and with  other  ECM proteins  providing  a  transport  system  for  the  cytokines  and  growth  factors. Activation of uPA after binding to uPAR converts plasminogen, a serine protease into its active form plasmin. Activated plasmin stimulates ECM degradation not only  by  direct  degradation  of  basement membrane  glycoproteins  but  also  by 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activating pro‐MMPs to MMPs[76]. Proliferation and angiogenesis continues in the  proliferative  phase  during  the  laying  down  of  a  new  ECM  and  the keratinocytes at  the edges of  the wound start migrating  towards  the center of the wound. Arrest of keratinocyte migration is often seen in chronic non‐healing wounds[77, 78].  
Remodelling leads to continued wound contraction and maturation of the ECM and eventually complete wound healing. Wound contraction which overlaps both the proliferative and remodeling phase is mainly dependent upon the myofibroblasts as these cells containing high concentration of actinomyosin can contract along lines of contraction[73]. This is supported by the release of cytokines like EGF that promote keratinocyte migration and re‐epithelialization[74]. In murine models expression of uPAR has been associated with tissue remodeling[79]. One of the important aspects of the phase of remodeling is the replacement of type III collagen by type I collage mediated by MMPs (matrix metalloproteinases), TIMPS (tissue inhibitors of matrix proteinases)[80] and TGFβ1[74]. Expression of at least two members of the MMP family (MMP‐2 and MMP‐9) is associated with an increase in active form of uPA[81] 
1.8 Cellular and molecular abnormalities in venous ulcer healing 
1.8.1 Keratinocyte migration  True wound healing  is  judged by  the ability of  the epidermal keratinocytes  to re‐epithelialise  and  cover  the  wound[82].  Similarly  in  venous  ulcer  healing epidermal  keratinocytes  play  a  critical  role.  It  has  been  shown  that  the keratinocytes at the edge of the venous ulcer are able to proliferate but unable 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to migrate  towards  the  centre of  the wound[77, 83].    The  formation of  a new and  healthy  epithelium  is  dependent  on  proliferation  and  migration  of keratinocytes  to  cover  the  epithelial  defect  of  the  wound[82].  Migration  of keratinocytes  in  turn  is  dependent  upon  a  number  of  factors  including  ECM, hypoxia, growth factors and protease activity [82, 84, 85].  
During  normal  wound  healing  the  keratinocytes  at  the  edge  of  a  wound  are stimulated after a  lag of 24‐48 hrs[86]. They start changing  their morphology, lose their hemidesmosomes and desmosomes and prepare for interaction with the  ECM.  As  there  is  no  basement  membrane  over  the  wound  the  plasma membrane of  the keratinocytes  starts  synthesizing a provisional matrix  in  the wound  bed,  while  keeping  contact  with  the  basement  membrane  collagens (type  IV  and  VII)  and  interstitial  collagens  (type  I,  III  and  VI)[87].  This  also results  in  the release of various growth factors and cytokines  into the ECM by the keratinocytes and the surrounding fibroblasts. Whether ECM or the growth factors  are  independently  important  for  the  initiation  and  augmentation  of migration of keratinocytes has been a matter of debate[87, 88]. Both  the ECM and growth factors have important roles in the migration of keratinocytes, with the  latter  stimulating keratinocyte migration  in  the presence of  a pro‐motility ECM  matrix[89].  In  the  initial  phase  of  wound  healing  type  III  collagen  and fibronectin  are  deposited  in  the  wound  bed  and  later  on  type  III  collagen  is replaced by type I collagen. This type I collagen is considered indispensable for a pro‐motility ECM.[90‐92], and helps the migration of  keratinocytes. 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The  question  that  still  remains  unanswered  is  why  in  some  venous  ulcers keratinocytes proliferate and migrate  to  re‐epithelialise  the wound, but  fail  to do that in others. 
 






1.8.4 Imbalanced proteolysis  During tissue remodelling cells move through tissue barriers. This movement is facilitated  by  regulation  of  specific  proteinases  that  digest  local  extracellular matrix  (ECM)  proteins  without  causing  significant  damage.  Degradation  and remodelling of ECM is therefore an important step in wound healing[104].  Matrix metalloproteinases (MMPs) are a growing family of endopeptidases that degrade  structural  proteins[105].  They  are  classified  into  collagenases, gelatinases,  matrilysins  and  membrane  type  MMPs[80].  The  optimal  level  of proteolytic activity is maintained through the concomitant expression of tissue inhibitors of metalloproteinases (TIMPs). So far 4 types of TIMP and 23 types of MMPs have been discorvered[80]. Imbalanced proteolytic activity mediated by MMPs has been  strongly  associated  in  the pathogenesis  of  venous ulcers[106, 107].  Most  studies  suggest  increased  activity  of  MMP‐1,  MMP‐2,  MMP‐3  and MMP‐9 activity  in venous ulcers and  lipodermatosclerotic skin[105, 108, 109], but  this  is dependent upon presence of other  factors  such as  tumour necrosis factor alpha (TNF‐α)[110] the activity of other proteases such as uPA[111], and 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metalloproteinases  like  MMP‐10  which  is  co‐expressed  with  MMP‐2  at  the epithelial  border  of  venous  ulcers[105].  Levels  of  both  uPA  and MMP‐9  have been  shown  to  be  significantly  higher  in  the  chronic  wound  exudates  when compared  with  exudates  from  acute  wounds,  suggesting  uncontrolled proteolysis within  the  environment of  chronic wounds[81].  The ECM can  also modulate the secretion of MMPs as suggested by the inhibitory effect of native fibronectin  on  proMMP‐9  secretion  when  compared  with  fragmented fibronectin[110].  A  decrease  in  the  levels  of  MMPs  following  compression therapy of venous ulcers has been observed suggesting an association between ulcer healing and MMPs[108].  Leak of plasminogen, acting as a persistent substrate for uPA also results in a potent pro‐proteolytic enviornment in the ulcer[81]. The plasmin that is generated from plasminogen can either directly degrade the ECM and basement membrane glycoproteins or indirectly cause this through activation of MMPs[76, 80]. Plasmin production is augmented by the action of plasminogen activators and inhibited by plasminogen activator inhibitors (PAI), which are all present within the environment of a venous ulcer[112]. 
 
1.9 Plasminogen activation system Components of the plasminogen system play an important role during different stages of normal wound healing, with plasminogen gene knockout mice having poor  wound  healing  when  compared  to  mice  with  combined  uPA  and  tPA knockouts[113].  The  presence  of  various  components  of  the  plasminogen system within the environment of a venous ulcer begs the question as to which 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component of this system has a major role to play in the healing of venous leg ulcers. 
















1.9.1 Plasminogen Plasminogen is made up of 791 amino acids and is primarily synthesised in the liver. It can be found in plasma at a concentration of 1.5 µmol/l with a half‐life of 2  days[114].  It  is  made  up  of  a  single  protease  domain  and  five  homologous 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kringle domains[115]. The first and fourth kringle domains impart high and low lysine  binding  affinity  respectively.  Based  on  the  lysine  binding  affinity plasminogen mediates its interactions with fibrin, cell surface receptors and its circulating  inhibitor  α2‐plasmin  inhibitor[114].  The  primary  function  of plasminogen is to cleave the insoluble fibrin polymers after its conversion to the active form. Plasminogen is converted to its active form plasmin after cleavage of a single peptide bond by the action of one of the two plasminogen activators, either  tissue‐type  of  plasminogen  activator  (tPA)  or  urokinase‐type  of plasminogen activator (uPA)[76]. In the absence of fibrin tPA is a weak activator of plasminogen[116] whereas uPA is an effective activator of plasminogen both in the presence or absence of fibrin[117] 
 
1.9.2 Plasmin Plasmin, a two‐chain molecule, is the activated form of plasminogen. It contains the classic serine protease catalytic triad (His‐Asp‐Ser) but it is a non‐selective serine protienase that can break down fibrin in addition to other proteins[114]. In addition plasmin can also activate other proteases and growth factors (TGF‐




(tPA) These  activators  have  similar  activities  but  are  two  enzymes  derived  from expression of two different genes[121, 122]. The gene coding for uPA is present on  chromosome  10  and  the  gene  encoding  for  tPA  is  on  chromosome  8[76]. Urokinase  plasminogen  activator  is  mainly  an  extra‐vascular  activator  of plasminogen  and  its  main  function  is  to  generate  pericellular  plasmin activity[123],  while  tPA’s  main  function  is  to  remove  cross  linked  fibrin  that forms in the vascular tree[124]. Due to this reason tPA has been used in clinical situations to dissolve clots 
Urokinase  plasminogen  activator  is  a  serine  protease  secreted  in  a  pro‐active (pro‐uPA)  form  having  a molecular  weight  of  54kDa[125].  It  is  synthsized  in kidney, lung, keratinocytes and endothelial cells[126]. Pro‐uPA is a single chain molecule (sc‐uPA) that undergoes conversion to the active two‐chain form (tc‐uPA), after cleavage of peptide bonds proteases including plasmin and kallikrein and angiogenic factor VEGF[127‐129]. The active tc‐uPA is usually referred to as uPA. Tc‐uPA exists either in high molecular form (54kD) or in a low molecular form (33kD) with the difference of a 135 amino terminal fragment between the two forms[117]. Both forms are active but whether there is a specific  function for  the  cleaved  low  molecular  form  still  remains  to  be  elucidated.  The  N terminal  A  chain  contains  the  epidermal  growth  factor  like  (EGF)  and  kringle domains, while the carboxy terminal B chain contains the protease domain. The EGF  domain  of  uPA mediates  its  binding with  the  uPA  receptor  (uPAR)[130]. Although  the  pro‐uPA  form  has  minimal  peptidase  activity  yet  it  can 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preferentially  activate  fibrin  bound  plasminogen,  presumably  because plasminogen undergoes a conformational change when it binds to fibrin making it more susceptible  to  the action of pro‐uPA[131]. Plasmin activates  the single chain  pro‐uPA  converting  it  into  the  two‐chain  form,  which  has  a  greater protease  activity  than  the  single  chain  pro‐uPA.  The  rate  at which  tc‐uPA  can cleave  plasminogen  is  200  times  higher  than  the  single  chain  pro‐uPA[132]. Plasma and urine concentration of uPA is 5‐10µg/l[126] 
The  second  plasminogen  activator  tPA  is  also  secreted  as  a  single  chain  form and is converted to the active two chain form by cleavage of a peptide bond by plasmin, kallikrein or coagulation factor Xa[126]. Plasma concentration of tPA is 5‐10µg/l and it is expressed by a number of cells including endothelial cells and keratinocytes[126].  Single  chain  tPA  contains  a  finger  domain,  growth  factor domain, kringle domain and the protease domain[76]. In addition to binding to fibrin  and  activating  the  fibrinolytic  system,  tPA  can  also  bind  to thrombospondin,  fibronectin  and  the  endothelial  cell  surface  which  also enhances its enzymetic activity[76] 
A  number  of  factors,  relevant  to  wound  healing  regulate  post‐transcriptional expression  of  uPA  and  tPA.  These  include  epidermal  growth  factor  (EGF), platelet derived growth factor (PDGF), transforming growth factor beta (TGFβ), Interlukin 1 (IL‐1) and glucocorticoids[76]. The presence of a specific cell bound uPA  receptor  (uPAR)  localizes  its  activity  to  the  pericellular  space.  This  is  an important function of uPA, as it  localises pericellular proteolysis to the leading edge of migratory cells[117, 133] 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1.9.4 Urokinase plasminogen activator receptor (uPAR) A specific extracellular uPA receptor (uPAR) was identified in 1985[134]. It is a glycosyl‐phosphatidylinositol (GPI) anchored protein made up of approximately 283  amino  acids  with  no  intracellular  component[123,  135].  This  receptor  is made up of  three domains, DI, DII  and DIII[123]. Although  the binding  site  of uPA  on  uPAR(CD87)  is  on  DI[136],  yet  the  complete  receptor  with  its characteristic  close  proximity  of  DI  and  DIII  is  necessary  for  ligand binding[137].  
The  interaction  of  uPA  with  uPAR  increases  the  ability  of  uPA  to  convert plasminogen  into plasmin. This  is due  to  the  fact  that  the binding of uPA with uPAR slows down the plasmin mediated degradation of uPA,  thereby allowing more conversion of plasminogen into plasmin[138]. Due to the GPI anchor uPAR can have variable positions on the plasma membrane depending upon the state of  the  cell,  so  that  on  a  resting  cell  uPAR  is  evenly  distributed whereas  on  a migrating  cell  it  can  cluster  onto  the  leading  edge[139].  uPAR  has  been identified  on  a  number  of  cell  types  including  fibroblasts,  monocytes, keratinocytes and endothelial progenitors[140‐143].  
Patients with paroxysmal nocturnal haemoglobinuria have a soluble form of the uPAR  receptor  (suPAR)  which  was  not  attached  to  the  cell  membrane[144]. Subsequent  studies  showed  the  existence  of  suPAR  in  various  pathological states  including  rheumatic  and  neurological  disease  and  in  various cancers[145].  Proteolytic  cleavage  between  DI  and  DII  can  result  in  the formation of two separate fragments, suPAR‐I and suPAR II‐III. Interestingly the 
cleavage of uPAR between D1 and D2 may be achieved by uPA[146] in addition to 
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other proteases[147]. If  the  cleavage  between  DI  and  DII  occurs  while  the receptor  is  attached  to  the  cell membrane  suPAR‐I  is  released and uPAR  II‐III remains attached to the cell membrane. Cleavage of uPAR by uPA is much faster on  the  cell  surface  compared  to  in  solution[148].  In  addition  the  cleavage  of uPAR  is  also  dependent  upon  its  glycosylation  pattern  as  the  heavily glycosylated uPAR (in ARO thryorid cancer cell line) is resistant to cleavage by uPA. In comparison a less glycosylated uPAR (in TAD‐2 thyroid cancer cell line) is easily cleaved by uPA. The cleavage of GPI anchor can result  in shedding of both  the complete  receptor suPAR‐I‐III and  the  fragments containing domains DI and DII‐III (Fig 4)[148‐150].  
The soluble forms of uPAR are found in a number of biological fluids including plasma, cystic fluid and ascitic fluid[145, 148]. uPAR and its fragments are also elevated  in  a  number  of  inflammatory  disorders,  during  angiogenesis  and  in certain cancers (e.g. gastric and prostate cancers)[148, 151]. 








1.10 Mechanisms of cell signalling by uPAR Urokinase plasminogen activator receptor is an extracellular receptor which in addition  to  its  proteolytic  function  of  activating  plasminogen  into  plasmin exhibits  additional  “extra‐proteolytic”  functions  e.g.  cell  adhesion,  cell migration,  chemotaxis  and  cell  differentiation[153‐156].  Being  a  purely extracellular  molecule  uPAR  is  dependent  upon  other  transmembrane molecules to manifest its intracellular functions. At least three transmembrane molecules  have  been  identified  through  which  uPAR  can  manifest  its  extra‐proteolytic  functions.  Given  below  is  a  brief  description  of  these  three mechanisms 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1.10.2 G protein coupled receptors (GPCR) The  other  transmembrane  molecules  with  which  uPAR  partners  for intracellular signalling are  the G  (guanine nucleotide binding) protein coupled receptors  (GPCR).  Of  all  the  GPCR  receptors  the  formyl  peptide  receptor  1 (FPRL1), a homologue of  fMLP (formyl‐Met‐Leu‐Phe), has been investigated  in more detail in respect to its interaction with uPAR. The chemotactic activity of uPA‐uPAR is dependent on FPRL1 as cells lacking this transmembrane receptor do not respond to uPA or suPARII‐III[151] 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1.10.3 Caveolin and lipid rafts Lipid  rafts  are  part  of  the  plasma  membrane  containing  cholesterol, gangliosides and GPI anchored molecules e.g. uPAR. Caveoli are a  type of  lipid raft  found  in  cell  surface  invaginations  implicated  in  endocytosis[151,  158]. uPAR colocalizes with the lipid rafts (GM1 and GM3) in a resting cell  but upon stimulation specific  types of  lipid rafts (GM3) having uPAR are stimulated and become localized to the functionally active part of the cell (e.g. the leading edge in  a  migratory  cell).  Therefore  the  subcellular  localization  of  uPAR  (either clustering  at  the  leading  edge  or  a more  generalized  distribution)  determines the type of signaling response (e.g. migration versus proliferation) [159]. 
 
1.11 Role for uPAR in wound healing  The  plasminogen  system  is  an  important  regulatory  mechanism  involved  in fibirnolysis. Components of this system have been identified in the environment of  non‐healing  ulcers.  However  the  plasminogen  system  has  additional  non‐proteolytic  functions that may have  implications  in venous ulcer healing. Most of  these  non‐proteolytic  functions  are  dependent  upon  the  receptor  uPAR, which therefore can have an important role in wound healing. Given below are some of the areas where uPAR mediated cellular responses may be involved in wound healing 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1.11.1 Cellular inflammatory response Urokinase  plasminogen  activator  receptor  is  increased  in  a  number  of inflammatory  disorders  including  rheumatic  disease,  HIV  and  inflammatory renal  diseases  etc[151].  It  may  therefore  influence  the  initial  inflammatory phase of wound healing as uPAR has shown to induce chemotaxis of neutrophils and monocytes[160, 161]. In addition keratinocytes involved in wound healing have shown an increased expression of uPAR[151]. Although the inflammatory potential of uPAR has not directly been observed in a wound environment, yet migration and adhesion of neutrophils  is shown to be  influenced by  increased monocytes uPAR expression[160, 162].  
 
1.11.2 Pericellular proteolysis The  urokinase  receptor  may  have  the  maximum  influence  in  wound  healing during pericellular proteolysis which facilitates the removal of degraded matrix components  making  the  ECM  suitable  for  cell  migration,  cell  adhesion  and angiogenesis[163].  Plasmin  generated  from  the  action of  uPA on plasminogen following  binding  to  uPAR  stimulates  ECM  degradation  not  only  by  direct degradation of basement membrane glycoproteins but also by activation of pro‐MMPs  to MMPs[76].  uPAR  localises uPA over  the  cellular  surface  and  thereby increases pericellular proteolysis[164], making the ECM more suitable for other cellular functions. 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1.11.3 Cellular proliferation Wound  healing  progresses  from  the  edge  of  a  healing  wound  that  starts  by keratinocyte  proliferation  followed  by  their  migration  towards  the  defect. Studies in uPAR gene knockout mice show that keratinocytes expressing uPAR proliferate much faster than those cells deficient in this receptor [165] 
 
1.11.4 Cellular chemotaxis The  DII‐III  domain  of  both  soluble  and  GPI  anchored  forms  of  uPAR  is responsible  for  cellular  chemotaxis.  One  of  the  first  studies  that  showed  the presence of a chemotactic peptiede at the linker region between DI and DII also suggested  that  this  function  of  uPAR  was  mediated  via  the  G  coupled proteins[154]. The DII‐III domain of suPAR may therefore have a potential role in inducing cellular chemotaxis during wound healing 
 
1.11.5 Cell migration & adhesion Variation  in  mechanical  stresses  may  lead  to  different  responses  in  healing wounds.  Both  the  ECM  and  the  cells within  a wound  respond  to  internal  and external mechanical  changes  by  exhibiting  changes  in  the  collagen  fibers  and cellular cytoskeleton[166, 167]. Interaction of uPA with intact uPAR containing the D1 domain can lead to cell migration independent of the proteolytic activity of  uPA.  This  uPA  dependent  cell  migration  may  be  carried  out  via  αVβ5 integrin[168]  or  GCRP[169].  In  cleaved  uPAR  lacking  the  D1  domain,  cell migration depends upon the binding of the chemotactic peptide SRSRY with N‐
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formyl peptide receptor (FPR) or FPRL1[170]. Cells expressing uPAR adhere to ECM  by  binding  to  VN  and  this  interaction  is  necessary  for  the  resulting cytoskeletal  changes  leading  towards  cell  migration[171].  In  instances  where there  is  no  direct  interaction  between  uPAR  and  VN,  uPA  can  lead  to  similar uPAR  dependent  cytoskeletal  changes[172].  Increased  cell‐matrix  adhesion  is vital for healing as it stimulates myofibroblast differentiation and formation of stress fibers[173]. In the presence of adhesive stimuli keratinocytes from uPAR knock‐out  mice  produced  much  reduced  deposition  of  laminin  5  when compared  with  keratinocytes  from  wild  type  mice[165],  signifying  the importance of uPAR in adhesion induced expression and deposition of  laminin 5, which is important for migration of keratinocytes.  
Evidence for the role of uPAR in cellular adhesion and migration is supported by impaired  neutrophil  infiltration  and  reduced  monocytes  adhesion  in  uPAR deficient  mice  in  response  to  Pseudomonas  aeruginosa  infection[160].  This however  may  only  be  a  uPAR  response  during  inflammation  and  not  during wound  repair.  uPAR‐VN  adhesion  and  resulting  cytoskeletal  changes  are enhanced [174, 175] by the presence of uPA. A possible explanation for this  is the  close  proximity  of  the  binding  sites  of  uPA  and  VN  on  uPAR,  with  uPA binding providing stability for VN binding[175] 
 
1.11.6 Angiogenesis Abnormal angiogenesis is linked with poor wound healing[95]. Although uPAR has  been  implicated  in  tumour  angiogenesis  it may have  an  indirect  or  direct role  in  angiogenesis  during  wound  healing.  uPAR  enhances  pericellular 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2.1 Patient recruitment and sample collection Ethical approval for the study was obtained from St Thomas’ Ethics committee (Ref:  09/H0802/4).  Potential  participants  were  identified  at  the  weekly  leg ulcer clinic at St Thomas’ Hospital. Patients aged >16years with leg ulcers, ankle brachial  pressure  index  (ABPI)  of  >0.8,  confirmed  venous  aetiology  at  venous duplex  and  starting  compression  therapy  were  included  in  the  study.  The exclusion criteria were ABPI ≤0.8, pregnancy, immunosuppressive therapy, age ≤16years or a non‐venous ulcer. Patients who satisfied the recruitment criteria were  informed  about  the  study  and  a  written  consent  was  obtained.  Blood plasma samples were obtained from ten patients only, as per instructions of the ethical committee.  
Ulcer  exudates  and  6mm  ulcer  edge  biopsies  were  obtained  from  each participant  at  start  of  compression  therapy.  Acute  wound  exudates  were collected from the skin donor sites of the patients undergoing split skin grafting. 
 
2.2 Collection of wound fluid Patients  were  asked  to  attend  the  hospital  in  the  morning.  The  ulcer  was cleaned  with  normal  saline  and  then  covered  with  a  transparent  occlusive 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dressing, Opsite® (Fig 1). Patients were then encouraged to drink and walk as much as possible, as walking resulted in a greater production of exudate. After 3‐4 hrs ulcer exudate accumulated underneath the Opsite® was aspirated with a needle. The exudate was then centrifuged at 16,000g at 4oC for 10mins and the supernatant aliquoted, were snap frozen and stored at ‐80˚C till needed. 
Acute  wound  exudates  were  collected  from  underneath  the  Opsite®  dressing placed  over  the  donor  site  of  patients  undergoing  split  skin  grafts  for  non healing  venous  ulcers.  Acute  wound  exudates  were  processed  similar  to  the chronic wound exudates 
 




2.3 Collection of ulcer tissue A  sample  of  ulcer  tissue  (6mm punch  biopsy) was  taken  from  the  ulcer  edge (including  a  rim  of  healthy  skin)  following  injection  of  1%  lignocaine  local anaesthetic,  The  collected  tissue  was  snap  frozen  at  ‐80˚C  for  biochemical analysis.   
2.4 Collection of blood plasma Blood  (10ml)  was  collected  from  the  superficial  anticubital  arm  veins  of  ten patients  using  a  21gauge  needle  at  the  time  of  collection  of  ulcer exudates/tissue samples. The collected blood was centrifuged at 400g and 4˚C for 15mins. Plasma was aliquoted, snap frozen and stored at ‐80˚C. 
 




2.6 Patient demographics A  total  of  thirty  venous  ulcer  exudates were  collected  (n=9  healers  and  n=21 non‐healers.  Tissue  biopsies  were  collected  from  27  patients.  Out  of  these  7 biopsies were from healers and 20 from non‐healers. Age, sex and average ulcer size  of  the  patients  are  given  in  table  1  and  2.  There  was  no  significant difference between the two groups from which wound exudates was collected. The  only  significant  difference  between  the  two  groups  from  which  tissue biopsies were taken was younger age of patients in healers. Acute wound fluids were obtained from 7 patients. 
Table  1:  Comparison  of  demographics  and  ulcer  size  between  patients  from 
whom wound exudates were collected. Ulcer size was expressed as the product of 
two largest diameters 
 Healers Non-Healers P value 
Total number 9 21  
Median age    
(yrs, range) 
62 (36-79) 70 (40-92) NS 
Sex (M:F) 4:5 10:11 NS 
Median ulcer 
size (cm2 range) 






 Healers Non-Healers P value 
Total number 7 20  
Median age    
(yrs, range) 
55 (36-79) 72 (36-88) <0.05 
Sex (M:F) 4:3 8:12 NS 
Median ulcer 
size (cm2 range) 




Chapter  3:  Validation  of  suPAR  ELISA  in  ulcer  tissue  and 
wound fluids 
 
3.1 Introduction Specific  immunoassays  for  detection  of  soluble  froms  of  uPAR  (DI‐III,  DI,  and DII‐DIII)  have  been  validated  for  human  plasma  samples[180]  but  not  for human wound exudates or tissue homogenates from wound biopsies. 
The  aim  of  this  part  of  the  study  was  to  validate  time‐resolved  fluorescence immunoassays (TR‐FIAs), used for plasma analysis of suPAR and its fragments, for measurement of these analytes in venous ulcer tissue and wound exudates.  For this specificity, linearity, accuracy and intra‐assay precision of the assay for wound exudates and tissue lysates was analysed. 
 
3.2 Methods   
3.2.1 Extraction of plasminogen components from tissue Polytetrafluoroethylene  (PTFE)  cups  and metal  balls,  used  to  pulverise  tissue samples  (Mikro  Dismembrator,  Sartorius),  were  equilibrated  with  liquid nitrogen.  Ulcer  tissue  samples  were  weighed  (whilst  frozen)  prior  to  being pulverized in the dismembrator at 3000rmp for 60secs. Extraction buffer (0.1 M Tris‐HCl, pH 8.1, 1% Triton X‐114, 10mM EDTA, 10µg/ml Aprotinin (the latter 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added  immediately  prior  to  tissue  extraction)  was  then  added  to  the  tissue powder (1ml per 100mg of  tissue) and the suspension pulverised at 3000rmp for  a  further  60secs.  The  homogenate was  pipetted  from  the  cups  into  1.5ml conical polypropylene tubes (Eppendorf) and centrifuged at 16,000g and 4oCfor 10mins.  The  supernatant  was  aliquoted,  snap  frozen  in  liquid  nitrogen  and stored at ‐80°C until assayed. 
 
3.2.2 TR‐FIAs of suPAR and its fragments in tissue lystaes and exudates Pooled wound fluid and tissue homogenate were diluted in Delfia assay buffer (Perkin  Elmer)  1:30  and  1:50  respectively.  Each  of  the  pool was  analysed  for selectivity,  loss  of  linearity,  inter‐assay  and  intra‐assay precision. During  each assay  a  quality  control  citrate  plasma  (diluted  1/5)  was  also  analysed.  The primary  and  secondary  antibodies  used  for  the  TR‐FIAs  were  a  gift  from  Dr Gunilla Hoya‐Hansen[180]. Primary monoclonal antibody  for TR‐FIA1 and TR‐FIA2  was  R2,  while  the  primary  antibody  used  for  TR‐FIA3  was  R5.  The detection  antibodies  used were  labelled with  europium.  For TR‐FIA1  and TR‐FIA3 the detection antibody used was Eu‐R3, and the detection antibody for TR‐FIA2  was  Eu‐R23[180].  Cross  reactivity  of  TR‐FIA3  for  suPAR  (I‐III)  was blocked by addition of peptide antagonist AE120[180] TR‐FIA1  measures  suPARI‐III;  TR‐FIA2  measures  suPARI‐III  and  suPARII‐III; TR‐FIA3 measures suPAR I. In order to get amount of suPARII‐III results of TR‐FIA1 are subtracted from TR‐FIA2. 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3.2.3 Depletion of suPAR Samples  diluted  in Delfia  assay  buffer were  depleted  off  suPAR  using  column chromatography.  Separate  columns  were  used  for  tissue  homogenates  and wound exudates. The steps used in depletion are as follows 
1. A  1ml  HiTrap  Protein  A  HP  column  (GE  Life  sciences  17‐0402)  was washed with 20 ml of PBS. 2. Rabbit  polyclonal  anti‐suPAR  antibody  (1ml)  diluted  in  PBS  to  a concentration  of  50µg/ml  was  added  to  the  column.  The  eluate  was collected and re‐applied repeating the process a total of 5 times. 3. Column was again washed with 20ml of PBS. 4. Samples diluted in Delfia assay buffer were run through the column and eluate collected. The eluate was then re‐applied to the column, repeating the process a total of 3times. The final collected eluate was the depleted sample. 
 
3.2.4 Time resolved immunoassays TR‐FIA1 was used for detection of intact suPAR (I‐III), TR‐FIA2 for detection of suPAR (I‐III) & suPAR (II‐III) and TR‐FIA3 for suPAR(I). Total suPAR (II‐III) was calculated by subtracting the results of TR‐FIA2 from TR‐FIA1.  One  volume  of  primary  antibody  was  diluted  in  six  volumes  of  a  0.01MHCl solution.  After  5mins  the  acidified  primary  antibody  was  diluted  in  a  0.1M NaH2PO4  solution  to  get  a  final  concentration  of  1µg/ml  for  the  primary antibody.  This  solution  was  used  to  coat  the  White  Maxisorb  (NUNC) fluorostrips (200 µl per well), which were  left overnight at room temperature 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after covering with plastic cover slips. The next day plates were washed twice with  Delfia  wash  solution  and  blocked  with  a  solution  containing  50mmol NaH2PO4,  1g/L  diazolidinyl  urea,  60g/L  sorbitol  and  1g/L diethylenetriaminepentaacetic  acid purified BSA  (300µl  per well). Plates were sealed and stored overnight at 4°C. Plates were emptied, dried in a fume hood for 3hrs and resealed.. The coated plates were stored for up to 4wks at 4°C prior to use. for the time resolved immunoassays. 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 2.51 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3.4 Discussion  The results of thse experiments show that the TR‐FIA 1, 2 and 3 can be used to measure  suPAR  and  its  fragments  in  wound  exudates.  The  generally  poor validation  results  for  tissue  homogenates  (selectivity,  linearity  and  precision) may  have  been  the  result  of  the  high  level  of  interference  by  substances  or matrix  revealed  by  the  depletion  studies,  even  though  linearity  on  the whole was  reasonable.  These  assays  were  therefore  considered  not  fit  for  use  in quantifing suPAR forms in tissue homogenates and were therefore only used to quantify suPAR forms in wound exudates in the subsequent experiments in this thesis. 
The  plasminogen  system  consists  of  many  components  including  uPA,  uPAR  and  the  inhibitors PAI‐1  and PAI‐2,  and  therfeore  an  ideal  extraction  solution (buffer) should be capable of extracting all the components of the plasminogen system. Some buffers give a higher extraction efficiency of PAI‐1 at the expense of uPA and uPAR, whereas others are potent extractors of uPAR only[181]. One solution  to  this  problem  is  to  use  different  extraction  buffers  on  the  same sample in order to obtain the maximum amount of uPAR, uPA and PAI. This was not possible in this study as the tissue amounts of ulcer tissue available from the 6 mm punch biopsy were too small to carry out all the possible extractions. We therefore  used  an  extraction  solution  that  optimally  extracted,  uPAR  [181]  as this was the main focus of this project. 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Chapter  4:  Quantification  of  suPAR  and  its  fragments  in 
wound exudates and plasma 
 
4.1 Introduction The amount of suPAR and its fragments (suPAR I & suPAR II‐III) was measured in  venous  ulcer  exudates,  acute wound  exudates  and  blood  plasma  using  TR‐FIAs. The aim was to compare the difference in expression of these fragments in healing and non‐healing venous ulcers. Relationship between systemic and local expression of suPAR fragments was also analysed 
 
4.2 Methods The methods used were similar to the ones used for validation of suPAR. Each wound exudate sample was diluted to 1/15 in delfia assay buffer (PerkinElmer). Levels of suPAR and its fragments were adjusted according to the total soluble protein  content  of  each  sample.  Levels  of  suPAR  and  its  fragments  obtained from venous ulcer and plasma of same patients were also compared  to assess any  relationship  between  systemic  and  local  expression  of  suPAR  and  its fragments. 
Levels of suPAR fragments were calculated in both nanogram per milliliter and nanogram per milligram of soluble protein. There  is no standard method used for measurement  of micromoleclues within wound  fluids.  In  previous  studies 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proteins  and  cytokines  within  wound  fluids  have  been  measured  both  in relationship to volume of fluid[182] as well as soluble protein content[95]. The main  reason  to  standardize  measurement  of  samples  according  to  soluble protein content of  the sample  is  to nullify  the effect of hydration, heart  failure and bacterial contamination[183]. We have therefore utilized both methods.  
 
4.3 Results  
4.3.1 suPAR I‐III in wound exudates When  samples  were  standardized  to  mg  of  solule  protein  healers  and  acute wound  fluid  (AWF)  had  significantly  higher  levels  of  complete  suPARI‐III compared  to  non‐healers.  The  levels  of  suPARI‐III  between  AWF  and  healers were  similar  with  no  statistically  significant  difference  (Table  13,  Fig  10). Measurements in mg/ml showed significantly higher level of suPARI‐III in AWF compared  to  healers  that  had  a  significantly  higher  level  than  non‐healers (Table 14, Fig 11). Statistical tests were performed using unpaired t test and a P value of <0.5 was considered significant. 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Table  13.  Comparison  of  suPARI­III  levels  (nanogram  per milligram  of  soluble 




































Table  14:  Comparison  of  suPARI­III  levels  (nanogram  per  milliliter)  in  AWF 

































4.3.2 suPARI in wound exudates Measurements  in ng/mg of  soluble protein  showed higher  levels of  suPARI  in healers  compared  to non‐healers  (Table 15, Fig 12). Comparison of AWF with healers  and  non‐healers  did  not  show  any  statistically  significant  difference. Statistical  tests  for  samples  measured  in  ng/mg  of  soluble  protein  were performed  using  unpaired  t  test  as  the  data  was  normally  distributed. Measurements  in  ng/ml  did  not  show  any  significant  difference  between  the samples (Table 16, Fig 13). Statistical tests for samples measured in ng/ml were performed  using  Mann Whitney  test  as  data  was  not  normally  distributed.  P value of <0.5 was considered significant 
 
Table  15.  Comparison  of  suPARI  levels  (nanogram  per  milligram  of  soluble 






Figure  12:  Comparison  of  suPARI  levels  (nanogram  per  milligram  of  soluble 
































































Table  17.  Comparison  of  uPARII­III  levels  (nanogram  per  milligram  of  soluble 
protein)  in  AWF  (acute wound  fluids),  healing  and  non­healing  ulcer  exudates. 






































































Table  19:  Comparison  of  plasma  suPAR  fragments  (nanogram  per  milliliter) 























































































r= 0.2, P= 0.4































r= 0.3, P= 0.3































4.4 Discussion There  was  significantly  higher  levels  of  all  forms  of  suPAR  in  healing  ulcer exudates  compared with non‐healing ulcer  exudates  suggesting  a  role  for  this receptor in ulcer healing. Whether samples were measured in ng/ml or ng/mg of soluble protein suPARI‐III and suPARII‐III levels were significantly higher in healing  ulcer  exudates  compared  to  non‐healing  ulcer  exudates.  Comparisons with AWF were also made to see if the environs of the healing venous ulcer bore any  resemblance  to  that of  an acute wound with  respect  to  suPAR  levels. The results obtained show that AWF has lower levels of suPAR II‐III compared with 
r= -0.5, P= 0.1



























exudates from healing ulcers (and to a lesser extent exudates from non‐healers). The  greater  amounts  of  this  fragment  found  in  ulcer  exudates  as  a  whole supports the possibility of a role for this peptide in healing chronic wounds. 
Soluble  urokinase  receptor,  containing  the  chemotactic  peptide  (suPARII‐III) that regulates cellular chemotaxis[154, 170] does not have a role in proteolytic activation  of  the  plasminogen  system.  This  fragment  appeared  to  be  the  best discriminator  between  healers  and  non‐healers,  suggesting  that  other  non‐proteolytic activities of uPAR may be involved in ulcer healing.  
The urokinase  receptor  is an extracellular protein  that  is dependent on  trans‐cellular proteins like integrins for regulating cellular functions[152], suggesting possibility  of  interaction  with  other  micromoleclues  within  the  ulcer environment. Animal  ulcer models  show  that  cellular processes  important  for ulcer healing rely on expression of uPAR on cell surface, including keratinocyte proliferation  and  migration[165],  angiogenesis[184]  and  inflammatory  cell infiltration[145].  Murine  keratinocytes  from  uPAR  knock‐out  mice  migrate more  slowly  than keratinocytes  from wild  type mice[165].  It  remains unclear, however  as  to  which  of  these  pathways may  be  activated  in  ulcer  healing  in man.  What  stimulates  increased  expression  of  suPAR  in  healing  ulcers  or inhibits its expression in non‐healing ulcers, merits further investigation. 
Previous studies have suggested release of suPAR into the blood from patients with advanced breast and colon cancers[185] as well as within biological fluids (urine) of healthy volnteers[186]. Ulcer exudates represent a filtrate of plasma together with  factors  secreted by  cells. We wanted  to  investigate whether  the levels  in the exudates  from chronic venous ulcers would be reflected  in blood. 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The  levels  of  circulating  suPAR  and  its  fragments  were  orders  of  magnitude lower than in the exudates, suggesting that there is a substantial contribution to suPAR  exudate  levels  from  the  local  wound  tissue.  We  found  no  correlation between  suPAR  levels  in  exudates  and plasma,  but  these  conclusions must be assessed  with  caution  due  to  the  fact  that  only  small  sample  numbers  were available for this analysis. 
The restriction to 10 blood samples by the eithcal committee prevented a useful interpretation of  the  results. After analyzing  the plasma samples a  substantial amendment was submitted to the eithcal committee for increasing the number of  plasma  samples.  This  however  was  not  very  useful  as  it  was  only  done towards  the  end  of  the  study  after  the  validation  experiments. We  hope  this based on our  limited plasma sample  results  future  studies will  be given more linency for obtaining blood samples. 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Chapter  5:  uPA  protein,  uPA  activity  and  PAI‐1  levels  in 
venous ulcer tissue and wound exudates 
 
5.1 Introduction The  amount  of  total  urokinase  activator  (uPA)  is  higher  in wounds  compared with  healthy  skin  [117,  187].  Higher  expression  in  addition  to  increased bioactivity of uPA  is also seen  in venous  leg ulcers[112]. Other components of plasminogen system e.g. PAI‐1 is also present within the environment of venous ulcers, where it is reported increased compared with normal skin[179]. 
The  aim  of  this  section  of  this  thesis  was  to  determine  whether  there  was  a difference  in  the  amount  and  activity  of  these  componets  of  the  plasminogen system in the environs of healing and non‐healing venous ulcers.  
 
5.2 Method for measuring total uPA Total uPA was measured using a commercially available ELISA kit (IMUBIND®; American  Diagnostica),  which  contained  a  96‐well  plate  pre‐coated  with primary antibody.  It has been designed  to measure all  forms of uPA  including receptor bound uPA as well as uPA bound to PAI complexes in wound exudates and tissue homogenates (American Diagnostica).  
Statistical analysis between the groups was performed by using Mann Whitney test and a P value of <0.05 was considered significant. As described previously 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5.2.2 Assay steps 1. Duplicate wells were filled with 100µl of standard or diluted samples. 2. Plate was covered with a plastic seal and incubated overnight at 4°C.  3. The next day plate was washed with wash buffer 4‐times. 4. 100µl  of  detection  antibody  was  added  to  each  well.  The  plate  was covered with a plastic seal and incubated at room temperature for 1hr. 5. Plate was washed again 4‐times, with the wash buffer. 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6. For  a  96‐well  plate  12µl  of  enzyme  conjugate  was  added  to  12ml  of enzyme  conjugate  diluent.  100µl  of  the  diluted  enzyme  conjugate  was added to each well, followed by sealing and incubating the plate for one hour. 7. Plate was washed again 4‐times, with the wash buffer. 8. 100µl  of  substrate  solution  was  added  to  each  well.  The  plate  was covered and incubated for 20mins while protecting it from light. 9. The reaction was stopped by adding 50µl of stop solution per well.  10. The absorbance of each well was measured using in a microplate reader (Spectromax, Moledular Dynamics) at a wavelength of 450nm.  




1. Sheep anti uPA antibody: obtained from Prof Patrick Gaffney (National Institute for Biological Standards and Controls, NIBSC).     2. Wash buffer: 0.05% of Tween20 in phosphate buffer saline (PBS). 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3. Blocking buffer: 1% bovine serum albumin in PBS. 4. Chromogenic substrate: S2251 chormogenic substrate (ChromogeniX)  (2ml) and 40µl of lys plasminogen diluted in 8ml of wash buffer.  
5.3.2 Assay steps 1. Sheep anti  uPA antibody was  coated on a 96 well  plate 100µl  per well after  diluting  10µl  of  the  antibody  in  10ml  of  Phosphate  buffer  saline (PBS).  2. The plate was then incubated at 4°C overnight.  3. Next day plate was washed 4 times with wash buffer.  4. Plate was blocked, by adding 200µl of blocking buffer in each well. It was then incubated at room temperature for one hour.  5. After another 3 washes standards and samples were added in duplicates, 100µl per well.  6. The plate was reincubated at 4°C overnight.  7. Next day plate was again washed 3 times with wash buffer 8. 100 µl of S2251 subtsrate was added to each well.  9. Plate was incubated at room temperature while shaking 10.  Readings were taken at 405nm at 1, 2 and 3hrs. 
Chronic wound exudates, acute wound fluids (n=7) and all tissue homogenates were  analysed  for  the  presence  of  uPA  activity.  The  standards  were  in  the concentration  range  0.01‐100IU/ml.  Chronic  wound  fluids  were  diluted  to 1/2.5, 1/5, 1/10 and 1/40, and acute wound fluids, 1/5, 1/10, 1/50 and 1/100. Tissue  homogenates  were  diluted  to  1/10,  1/50  and  1/100.  Correlation 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between  active  uPA  within  tissue  homogenates  and  total  PAI‐1  was  also analysed. 
 











5.5.1 uPA protein Wound exudates from 9 healers and 21 non‐healers were analysed for total uPA protein.  There  was  no  significant  difference  in  the  levels  of  uPA  found  in exudates  from  healing  and  non‐healing  venous  ulcers  using  both  methods  of measurement (Table 20,21. Fig 22, 23). Acute wound fluids had a significantly higher  level  of  total  uPA  when  compared  with  non‐healing  exudates  (Table 20,21). 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Table  20:  Comparison  of  total  uPA  level  (nanogram  per  milligram  of  soluble 






between  AWF  (acute  wound  fluids),  healing  and  non­healing  ulcer  exudates. 
Statistical analysis by Mann­Whitney test 































Table  21:  Compaison  of  total  uPA  level  (nanogram per millliter)  between AWF 








Figure 23: Compaison of  total uPA  level  (nanogram per millliter) between AWF 
(acute wound fluids), healing and non­healing ulcer exudates. Statistical analysis 
by Mann­Whitney test 
 UPA  protein  was  measured  in  20  non‐healing  and  7  healing    tissue homogenates.  Samples  in which  uPA  levels were  below  detection  level  of  the ELISA (2 non‐healing and 1 healing ulcer homogenate) were given a value 1/10 of the lowest standard. There was no significant difference in total uPA antigen levels  in  tissue  homogenates  obtained  from  healing  (mean  2.23ng/mg±1.67) and non‐healing (mean 1.41ng/mg±0.97) leg ulcers (P=0.27, Fig 24).  
 




















































































Figure  26:  Comparison  of  active  uPA  (milligarm  per  milliliter)  in  tissue 
homogenates obtained  from healing  and non­healing ulcers.  Statistical  analysis 
by Mann Whitney test. 
 






































































5.5.5 Quantification of PAI‐1 in exudates and tissue homogenates  When results were calculated according to soluble protein of the sample there was  over  twice  as much  PAI‐1  in  exudates  collected  from  healers  than  those from with non‐healers, but this did not reach significance (P=0.09, Table 23, Fig 28). Acute wound fluids had lowest levels of PAI‐1 compared with healing and non‐healing exudates (P=0.0007 ‐ healers, P=0.003 – non‐healers).  
Comparing the samples in ng/ml still showed lowest levels of PAI‐1 in AWF but the  only  statistically  significant  difference was  seen  between  non‐healers  and AWF (Table 24, Fig 29) 
There were higher  levels  of  PAI‐1  in  homogenates  obtained  from non‐healing ulcers  compared  with  healing  ulcers.  The  difference  was,  however,  not significant (P=0.09, Fig 30). 
 
Table  23:  Comparison  of  PAI­1  levels  (ng  per  milligram  of  soluble  protein) 



































































































5.6 Discussion  It has been suggested that uPA in venous ulcers has a role in ECM degradation, either  directly  through  activation  of  plasmin[188]  or  indirect  by  activating MMPs[80]. Our results show that there was no difference in the amount of total uPA  protein  and  PAI‐1  present  in  exudates  obtained  from  healing  and  non‐healing  venous  ulcers.  Both  uPA  and  PAI‐1  were  measurable  in  all  tissue homogenates,  with  no  statistical  difference  between  healing  and  non‐healing ulcers.  This  may  suggest  a  generally  increased  fibrinolytic  response  within venous ulcers[112], but based on our results it is not possible to suggest a direct role for uPA or PAI‐1 in ulcer healing.  
r= -0.2, P=0.17


























A  possible  role  of  uPA may  be  the  cleavage  of  suPAR  between DI  and DII‐III. Cleavage of uPAR at the linker region between DI and DII‐III can be induced by a variety of proteases in vitro[147], but so far only uPA can cleave this region in vivo[146]. Again  as  there was no difference  in uPA between healing  and non‐healing ulcers it is not possible to speculate that this may be a role of uPA which may lead to healing of a venous leg ulcer. 
PAI‐1 is known to influence a variety of cellular functions[189] e.g. cell motility and  angiogenesis  that  are  important  processes  in  wound  healing[93,  96]. Studies  using  animal models  have  shown  that  PAI‐1  is  required  during  early wound healing especially during cell migration[190]. The finding of lower levels of PAI‐1 in AWF compared with both healing and non‐healing ulcer exudates is consistent with that of a previous study[81]. Angiogenesis is pivotal for normal wound  healing[93]  and  in  murine  model  PAI‐1  has  been  shown  to  inhibit angiogenesis  at  higher  doses,  while  promoting  angiogenesis  at  a  lower doses[191]. It is therefore possible to speculate that, PAI‐1 has a pro‐angiogenic role at lower concentrations found in acute wounds and an anti‐angiogenic role at  the  higher  concentrations  of  the  chronic  wound  environment.  This  will however need further studies to confirm this hypothesis. 
Our results comparing healing and non‐healing venous ulcers have not shown a significant difference in the levels of PAI‐1, in both tissue homogenates and the wound  exudates.  Based  on  our  results we  cannot  draw  firm  conclusions  on  a role  for PAI‐1  in ulcer healing. Also we were unable  to differentiate  the active and inactive/latent forms of PAI‐1 as the ELISA kit we used for determination of 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PAI‐1 measured both form and could not differentiate between the two forms of PAI‐1. 
The  results  of  PAI‐1  in  tissue  homogenates  and  wound  exudates  were contrasting as tissue homogenates from non‐healers had higher levels of PAI‐1 compared  with  tissue  homogenates  from  healers  whereas  healing  wound exudates had higher levels of PAI‐1 compared with non‐healing exudates. This may  be  because  of  the  increased  presence  of  vitronectin  within  the  tissue matrix, to which PAI‐1 can bind and stabalize [192]. 
No  uPA  activity  was  detected  in  any  ulcer  exudate  or  wound  fluid  analysed. Non‐healer tissue homogenates had higer uPA activity compared to healers but this  was  not  statistically  significant.  Active  uPA  has  been  found  in  the granulation tissue and ulcer edges of healing wounds[143, 177]. Active uPA may be affected by PAI‐1 but we did not find any correlation between active uPA and PAI‐1. This however was not  an  ideal  assessment,  as  the method we used  for detecting PAI‐1 could not differentiate between active and latent form of PAI‐I. Therefore  further  studies  to  analyze  the  role  of  active  PAI‐1  on  uPA  activity would clarify its role in venous ulcer healing.  





6.1 Introduction Wound healing is defined as complete re‐epithelialisation of an epithelial defect. In order  to achieve  this keratinocytes at  the ulcer edge must migrate  towards the centre of the wound. The peptide 88‐92 (SRSRY) present at the linker region between domains I and II of uPAR is highly chemotactic for the monocytes cell line, THP‐1[154] and human embryonic kidney cells[170] 
We therefore aimed to determine whether the SRSRY chemotactic  fragment of suPARII‐III would affect chemotaxis of adult human keratinocytes (HEKa).  
Initially  migration  of  THP‐1  cells  (immortal  human  monocytic  cell  line)  was analysed  in  vitro  using  commercially  prepared  chemotactic  peptide  88‐92  to validate  our  experimental  conditions.  This  was  followed  by  analysis  of migration  of  HEKa  in  response  to  chemotactic  peptide,  control  (scrambled) peptide and the wound fluids in which levels of suPAR fragments have already been measured. 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6.2 Methods Initial  experiments  were  carried  out  using  THP‐1  cells  to  validate  the chemotactic  efficacy of  the SRSRY peptide  in our hands. This was  followed by analysis of the effect of the peptide and wound fluids on migration of HEKa.  









3. A  75cm2  flask  was  coated  by  adding  50µl  coating  matrix  (R‐011‐K), diluted in 5ml dilution media from the coating matrix kit. The flask was rocked  to  ensure  uniform  distribution.  Flasks  were  capped  and incubated  for  30mins  at  room  temperature.  Excess  coating matrix was removed and the flasks used immediately or stored at 2 to 8 °C for up to 6wks. 
4. The vial of keratinocytes was removed from the freezer and thawed in a 37°C water bath and viability assessed by taking a 20µl aliquot of the cell suspension and adding 20µl of trypan blue. The dye cell suspension was mixed  and  a  small  aliquot  placed  on  Neubauer  haemoctytometer (Hawksley).  The  number  of  cells  containing  trypan  blue  were enumerated using an inverted microscope (Olympus). 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5.  The contents of the vial were diluted in supplemented medium to obtain 2.5×104  viable  cells  per  ml  added  to  75cm2/25cm2  culture  flasks.  The flasks were then swirled to achieve even distribution of the medium and the cells incubated at 37°C with 5% CO2/95%. 
6. Approximately  half  of  the  medium  in  the  flask  was  removed  and replenished  after  48hrs.  Subsequently,  similar  media  changes  were carried out every 24hrs. 
 
6.2.2 Dissociation of HEKa cells from the flask for subculturing and use 1. Culture  media  was  removed  from  the  flasks  and  placed  in  a  sterile tube  to be used  later  for neutralisation of  the  trypsin EDTA solution used to disassociate cells from the flask.  2. 1  ml  of  trypsin/EDTA  (0.025%  trypsin,  0.01%  EDTA  in  PBS)  was added  to  25cm  flask  (2‐3ml  for  75  cm  flask).  Flasks  were  rocked gently so that the whole surface was covered followed by aspiration of all trypsin/EDTA after 1min (60 seconds) and incubation at 37°C with 5% CO2 for a further 5mins.  3. The  sides  of  the  flask  were  tapped  gently  to  dislodge  cells,  3ml  of culture  media  (9ml  for  75cm)  was  added  to  neutralise  the trypsin/EDTA  and  the  cell  supension  transferred  to  a  50ml  falcon tube. 4. The  flask was washed with  a  further  3ml  of  culture media  (9ml  for 75cm), which was  then decanted  into  the  falcon  tube  containing  the cells. 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(Hawksley). The number of cells containing trypan blue (dead cells) was enumerated using an inverted microscope (Olympus). 5. The contents of the vial were diluted by addition of the prepared culture media. Cells were then put into the culture flasks at concentration of 3×105 viable cells/ml. The culture flasks were then placed in the incubator at 37°C with 5% CO2 6. Cells were allowed to grow in the culture media till the concentration reached 1×106 cells.  7. For subculturing the cell culture media containing the cells was placed in a 50ml falcon tube. This was centriguged at 100g for 5 mins. After spinning the supernatant fluid is carefully aspirated without disturbing the cell pellet. Cellular pellet was then resuspended in 1ml of media and counted as before using a haemocytometer. 8. This was followed by a further subculture or cells were frozen for storage. Cellular concentration for storage was 6×106 THP‐1 cells/ml.  
 
6.2.4 Chemotaxis analysis using the Boyden Chamber A modified Boyden chamber, with an 8µm pore membrane separating the two chambers  (BD  351164),  was  used  for  analysis  of  chemotaxis.  Cells  from  a culture  flask  were  spun  (at  180g  for  7mins  for  HEKa  &  at  100g  for  5mins) resulting  in  formation of  a  cell pellet. This was  resuspended  in 1ml of  culture media. Calcein AM (Invitrogen, C1430) at 10µM concentration was added to 1ml of this culture media containing the required cells. After a 3minute interval, 5ml of  serum  free media was added  to wash away excess  calcein. This  suspension 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was  then  centrifuged  again  at  180g  for  7minutes  to  reform  the  cell  pellet. Required number of  cells were  taken and pipetted  in  the  top wells of 96‐well modified  Boyden  chamber  fluoroblok  plates  (~20,000  cell/well  for HEKa  and ~50,000 cells/well for THP‐1).  
During  the  course  of  the  experiments  optimal  coating  with  ECM  proteins (collagen, fibronectin and vitronectin) was also determined.   Chemoattractants and  serum  free media  (EpiLife)  as  negative  control was  placed  in  the  bottom wells. Each sample was measured in triplicates. Fluorescence was measured in the bottom chambers with the excitation and emission filters set at 485nm and 535nm respectively on a Victor fluorometer (Perkin Elmer). Each well was read for  0.5seconds.  For  keratinocyte  migration  reading  were  taken  at  40min intervals  going  up  to  4hrs.  For  THP‐1  cells  readings  were  taken  at  20min intervals going up to 2hrs. The effect of treatment on cell chemotaxis was taken as the ratio of fluorescence intensity in the treatment well to that of the negative control. All  analysis were performed using  two way ANNOVA with Bonferroni post‐test using PRISM Ver5. 
(i) SRSRY peptide as a chemotactic agent: Commercially prepared five  amino  acid  chemotactic  peptide  sequence,  similar  to  that  found within suPARII‐III serine‐argenine‐serine‐arginine‐tyrosine (SRSRY) was obtained from BaChem, UK. In addition a scrambled amino acid sequence with  same  five  amino  acids  but  different  sequence  was  obtained  from BaChem,  UK  and  used  as  a  control  peptide.  Chemotactic  potential  of HEKa  and  THP‐1  cells  was  assessed  by  placing  the  cells  in  the  upper 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chambers and the chemotactic or control peptide  in the  lower chamber of boyden chamber. All experiments were performed in triplicate  
(ii)  Effects  of  coating  with  different  ECM  proteins  ‐.  The  membrane containing  top well of  the Boyden chamber was coated with one of  the ECM proteins,  collagen  typeI  (Sigma  C8919),  fibronectin  (PHE0023)  or vitronectin  (PHE0011).  Desired  ECM  protein  (collagen,  fibronectin  or vitronectin)  was  diluted  to  10µg/ml  in  sterile  PBS,  which  was  then placed  in  the  bottom wells  (200µl/well).  Top wells were  then  inserted into  the  bottom  wells  and  incubated  at  room  temperature  for  2‐3hrs. This was  followed  by  a wash with  PBS  after which  the  top wells were used  for  the  desired  experiments.  All  experiments  were  performed  in triplicates   
(iii) Dilution  effect  of wound  fluids    ‐  A  pooled  exudate was  created from both healing  and non‐healing ulcer  exudates. HEKa migration  in response to various dilutions (2.5%, 5%, 10%, 15% and 20%) of pooled wound exudates that were placed in the lower chambers was observed. Wound  fluid  was  diluted  in  SFM.  All  experiments  were  performed  in triplicates 
(iv)  Healing  and  non­healing  exudates  –  Migration  of  HEKa  was observed in response to exudates obtained from healing (n=4) and non‐healing  (n=9)  ulcers.  As  determined  by  the  dilutional  experiments  all wound  exudates  (healer  and  non‐healer)  were  at  5%  dilution.  All experiments were performed in triplicates 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(v) Depletion of sUPAR  ‐ Depletion of suPAR was carried out on a pool of healing and non‐healing exudates by affinity column chromatography as described in chapter3, section3.2.3. Migration of HEKa in response to depleted  healing  and  non‐healing  ulcer  exudates  was  assessed.  All experiments were performed in triplicates 
 
6.2.5 Scratch assay Scratch assays were also used to assess keratinocyte migration. HEKa cells were incubated  at  8000‐cells/well  in  a  24‐well  plate  coated  with  typeI  collagen (Sigma C8919).   Once the HEKa cells reached >80% confluence scratches were made  in  the  cultured  cells,  in  the  centre  of  each  well,  using  a  sterile  200µl pipette tip, after which the media containing detached cells was aspirated and replaced  with  serum  free  media  (SFM)  with  chemotactic  peptide,  SFM  with scrambled  peptide  or  SFM with  varying  concentrations  of  wound  fluids  from patients  who  had  healing  or  non‐healing  venous  ulcers,  added.  Plates  were incubated  at  37°C,  5%  CO2/95%  air  humidified  cell  culture  incubator  and micrographs  of  each  scratch  taken  at  0,  12  and  24hrs.  All  experiments  were carried out in quadruplicate. 
(i) Proliferation or migration  Assays  were  repeated  in  the  presence  of  mitomycin  C,  which  is  a  potent inhibitor  of  cell  proliferation  in  order  to  determine  whether  any  scratch coverage  was  the  result  of  cell  proliferation  or  cell  migration.  Mitomycin  C (Sigma,  M4287)  at  concentration  of  4µl/ml  was  added  to  cell  cultures. Experiments with and without Mitomycin C were carried out on 4 non‐healing 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and  4  healing  ucler  exudates.  All  experiments  were  carried  out  in quadruplicates. 
   (ii) sUPAR depletion  
In order to determine whether suPAR has a role in in‐vitro wound healing, scratch assays were repeated after depleting suPAR from the ulcer exudates by affinity column chromatography (as described in chapter3 section3.2.3). Experiments were performed with three healing and three non‐healing ulcer exudates. One half of each ulcer exudate was depleted of suPAR and experiments were carried out with depleted and non‐depleted ulcer exudates. All experiments were carried out in quadruplicates. 
All  statistical  analysis were  performed using  two way ANOVA and Bonferroni post‐test with PRISM ver5 
 
6.3 Boyden chamber results  
6.3.1 Optimization of experimental conditions Initial migration  studies were  performed  to  validate  experimental  conditions. Commercial  chemotactic  peptide  (SRSRY)  induced  a  significantly  higher migration  in THP‐1  cells  at  concentratin  of  1picomole  (1pM)  and 1femtomole (1fM) compared to similar concentrations of control (scrambled) peptide after 60 mins (p<0.0001, Fig 32). There was no difference in the migration of THP‐1 cells towards 1pM and 1fM of cheomactic peptide (Table 25) 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Fig  32:  Migration  of  THP­1  towrds  chemotactic  (SRSRY)  or  control/scrambled 
peptide  (C­pep).  SRSRY  induced  a  significantly  higher migration  of  THP­1  cells 
compared  to  control.  Statistical  analysis  using  two­way  ANNOVA.  Experiments 




























0   NS   NS   NS   NS   NS 
20   (NS)   (NS)   (NS   NS   NS 
30   (NS)   (NS)   (NS)   (<0.05)   (NS) 
60  (NS)   (<0.01)   (NS)   (<0.001)  (NS) 
90  (NS)   (<0.001)   (NS)   (<0.001)   (<0.05) 
120  (NS)   (<0.001)   (P<0.001)   (P=0.001)   (<0.001) 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Fig  33:  Migration  of  HEKa  towards  chemotactic  (SRSRY)  or  control/scrambled 
peptide  (C­pep).  Chemotactic  peptide  (SRSRY)  induced  a  significantly  higher 
migration  of HEKa  at  concentration  of  1picomole  compared  to  control  peptide. 





































0  NS  NS  NS  NS  NS 
40  <0.001  <0.001  <0.05  NS  <0.01 
100  <0.001  <0.001  <0.001  <0.001  <0.001 
200  <0.001  <0.001  <0.001  <0.001  <0.001 
280  <0.001  <0.001  <0.001  <0.001  <0.001 
360  <0.001  <0.001  <0.001  <0.001  <0.001  
 
6.5.2 Migration of HEKa in the presence of ECM proteins    We  also  optimize  HEKa  migration  in  the  presence  of  various  ECM proteins that can be found in the environment of a healing wound. Migration of HEKa  in  the  presence  of  collagen  (CN),  fibronectin  (FN)  and  vitronectin  (VN) was  analysed.  At  1pM  concentration  HEKa  cells  showed  significantly  higher migration towards chemotactic peptide compared to the scrambled peptide (Fig 33). There was however no significant difference between uncoated, CN coated, FN coated and VN coated wells at 1pM concentration except at 160mins, which returned to a non‐significant level at 200mins (Table 27) 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Fig 34: HEKa migration  towards  chemotactic  (SRSRY) or  control peptide  (C­
pep) in the presence of various ECM proteins. HEKa migration was higher at a 
concentration of 1picomole and in presence of collagen (CN) compared to the 
presence  of  no  coating,  vitronectin  (VN)  and  fibronectin  (FN).  Statistical 











































0  NS  NS  NS  NS  NS  NS 
40  NS  NS  NS  NS  NS  NS 
80  NS  NS  NS  NS  NS  NS 
120  NS  NS  NS  NS  NS  NS 
160  <0.001  <0.05  NS  NS  <0.001  <0.05 
200  NS  NS  NS  NS  NS  NS    










































































0  NS  NS  NS  NS  NS 
40   NS  NS  NS   NS  NS 
100  NS  NS  NS  NS  NS 
200  NS  NS   NS  <0.05  NS 
280   NS  NS  <0.05  <0.001  NS 






















0  NS  NS  NS  NS  NS 
40  NS  NS  NS  NS  NS 
100  NS  NS  NS  NS  NS 
200  NS  NS  NS  NS  NS 
280  NS  <0.01  NS  <0.05  NS 
360  NS  <0.001  NS  <0.001  <0.001 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6.5.4 Migration of HEKa towards healing and non‐healing wound exudates    HEKa migration was compared between healing and non‐healing wound exudates. Both healing and non‐healing wound fluids caused a variable migratory  effect  on  HEKa  cells.  There  was  no  differential  migration  of  HEKa towards  healing  or  non‐healing  exudates.  Some  of  the  non‐healing  exudates even resulted in higher HEKa migration compared to healing exudates (Fig 36). In  order  to  see  a  differential  effect  of  healing  or  non‐healing wound  exudates upon HEKa migration the mean of healing and non‐healing exudate results were plotted,  which  again  did  not  show  a  significant  difference  in  HEKa migration between healing and non‐healing exudates (Fig 37). 
Fig  36: Migration  of HEKa  towards  healing  (n=4)  and non­healing  (n=9) 
wound  exudates.  Statistaical  analysis  by  two way ANNOVA.  Experiments 
performed in triplicates  















































Fig  37:  Migration  of  HEKa  towards  healing  (mean)  and  non­healing 
(mean)  exudates.  NH=  non­healing  ulcer  exudate.  H=  healing  ulcer 
exudate. Statistical analysis by two way ANNOVA  
6.5.5 Migration of HEKa towards depleted wound exudates    To analyze the role of suPAR in HEKa migration boyden chamber assays were repeated using depleted healing and non‐healing wound exudates. Pools  of  healing  and  non‐healing  wound  fluids  were  depleted  off  suPAR  as previously described in chapter 3, using affinity column chromatography. These results  showed  a  higher migration of HEKa  towards  the depleted non‐healing wound  exudates  when  compared  to  the  depleted  healing  exudates  but  the results were not statistically significant using Bonferroni post test (P>0.05, Fig 38) 
 
P=0.01













































6.5.6 Optimization of wound exudate concentrations Initial experiment using 2% wound exudates resulted in cell death in all cells treated with both healing and non‐healing wound exudates. Scratch assays were  then  repeated  using  0.5%  of  both  healing  and  non‐healing  wound exudates. This resulted in complete healing of scratch in the healers whereas the  non‐healers  resulted  in  cell  death  at  end  of  24  hrs  (Fig  39,40). Quantitative  analysis  of  scratch  coverage between  the  two  groups  showed 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Fig 41:  Comparison of  scratch  coverage after  treatment with 0.5% healing and 
non­healing  wound  exudates.  Statistical  analysis  using  two  way  ANNOVA. 
Experiments performed in quadruplicates. 
 





























Fig  42:  Scratch  coverage  after  treatment  with  0.1%  healing  exudate.  Complete 
healing at 24hours. 
             
          0 hour        12 hrs           24 hrs 
 
Fig  43:  Coverage  of  scratch  after  treatment  with  0.1%  non­healing  wound 
exudate. Incomplete healing of scratch at 24hours. 
            





 Fig 44: Comparison of  scratch  coverage after  treatment with 0.1% healing and 
non­healing  wound  exudates.  Statistical  analysis  using  two  way  ANNOVA. 
Experiments performed in quadruplicates. 
 
































        0 hour           12 hrs         24 hrs 
 
Fig  46:  Scratch  coverage  after  treatment  with  1%  non­healing  exudate  in 
presence of Mitomycin C 
                   
0 hour                       12 hrs         24 hrs 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Fig  47:  Comparison  of  scratch  coverage with  0.1% healing  (n=4)  and  1% non­
healing  (n=4)  ulcer  exudates  in  presence  of  Mytomycin  C.  There  was  no 
statistically  significant  difference  in  the  presenc  or  absence  of  Mitomycin  C. 





















































0   NS   NS   NS 
12  <0.001  <0.01  NS 
24  <0.001  NS  NS  
 





0 hour      12 hrs          24 hrs 
 
Fig  49:  Scratch  coverage  after  treatment  with  suPAR  depleted  non­healing 
exudate 
         




Fig 50: Effect  of  suPAR depletion on HEKa  cell  viability.  (i) Keratinocytes  gated 
according to size and scatter properties with (ii) doublets excluded. (iii) Typical 





6.6 Discussion The commercial SRSRY peptide that is found on suPARII‐III was chemotactic for human  adult  keratinocytes  compared  with  a  scrambled  sequence  of  this peptide. The migration of HEKa  towards  all  exudates was higher  than  control (SFM).  Comparison  between  healers  and  non‐healers  revealed  no  significant difference in HEKa chemotaxis. Variability was high, with a substantially greater HEKa migratory  response  towards  some  non‐healing  ulcer  exudates  that  had lower levels of suPARII‐III. This suggests that suPARII‐III may not be a primary chemotactic stimulant to in‐vitro HEKa migration. 
This  possibility  was  further  proven  when  suPAR  was  depletd  from  the  ulcer exudates.  The  difference  between  depleted  non‐healing  ulcer  exudates  and depleted healing ucler exudates did not  increase and remained similar to non‐depleted  levels.  Possible  reasons  for  the  poor  chemotactic  effect  of  the  ulcer exudates could include the lack of other facilitative cell surface proteins such as integrins  and  GCRP  that  are  required  by  suPAR  to  influence  intracellular signaling and migration[152].   
The lack of effect of coating the membranes in the Boyden Chambers with ECM proteins was unexpected, as cells expressing uPAR adhere to ECM by binding to ECM  proteins  such  as  VN  and  this  interaction  is  necessary  for  the  resulting cytoskeletal  changes  leading  towards  cell  migration[171].  In  instances  where there  is  no  direct  interaction  between  uPAR  and  VN,  uPA  can  lead  to  similar uPAR  dependent  cytoskeletal  changes  independent  of  VN[172].  It  is  possible that  in  the  in‐vitro  environment of  the Boyden Chamber,  these  cells  either do 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not express the relevant proteins (as the HEKa cells were from healthy adult) or lack the required assistance from ECM to induce a migratory response. It is also possible  that  the  SRSRY  peptide may  be  an  important  chemotactic  factor  but within the complex wound environment it may be degraded to an inactive form by  proteases  found  within  a  wound  environment.  Evidence  to  support  this possibility  would  need  further  detailed  studies  to  identify  and  inhibit  in‐vivo proteases that may degrade suPARII‐III  
The results of the scratch assays showed that HEKa cells could not survive in the presence  of  high  concentrations  of  ulcer  exudates  (both  healing  and  non‐healing) in vitro. This suggests the presence of an inhibitory substance(s) within these  exudates.  At  lower  concentrations  healing  exudates  stimulated  HEKa coverage  of  scratch  compared  with  non‐healing  exudates.  Our  results  are  in contrast  with  a  previous  study  where  keratinocytes  survived  after  treatment with 2% chronic wound exudates for 24 hours[176]. A possible explaination for this difference may be that we diluted the wound exutades in serum free media in  order  to  see  the  true  effect  of  chronic  wound  exudates  where  as  in  the previously  done  study  the  authors  used  growth  meida  to  dilute  the  chronic wound exudates[176]. This would have provided the keratinocytes with growth supplements  that  may  have  prolonged  the  survival  despite  the  presence  of substances within the chronic wound exudates that would inhibit survival. 
Treatment  with  mitomycin  C  did  not  significantly  alter  scratch  coverage induced by  either healing or non‐healing ulcer  exudates,  suggesting  a  role  for cellular migration as opposed to proliferation in the response to treatment with exudates. The death of HEKa  in  the presence of  suPAR‐depleted exudates also 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The  exact  mechanisms  leading  from  venous  hypertension  to  venous  leg ulceration  still  remain  unclear.  We  have  proven  the  presence  of  suPAR fragments within the environment of venous ulcers. We have also attempted to clarify  the role of  suPAR  in venous ulceration as previous studies have shown increased  levels  of  plasminogen  components  within  venous  ulcers  when compared with normal skin[112, 177, 178].  In contrast to pervious studies we compared  levels  of  suPAR  fragments  and  other  components  of  plasminogen system  between  healing  and  non‐healing  venous  ulcers.  Amongst  the components of the plasminogen system that were examined suPAR appeared to be  the  only  difference  between  healing  and  non‐healing  ulcers.  Levels  of suPARI‐III and suPARII‐III were significantly higher in exudates obtained from healing venous ulcers  compared  to non‐healing venous ulcers. This difference remained significant irrespective of normalizing the level of suPAR according to volume (ng/ml) or soluble protein (ng/mg soluble protein).  
No  difference was  observed  in  the  levels  of  uPA  and  PAI‐1 when  healing  and non‐healing  venous  ulcers  were  compared.  The  lack  of  uPA  activity  in  ulcer exudates, suggests either the presence of an inhibitory protease or the fact that uPA may only have an active role in cellular environment. 
In a previous study treatment of keratinocytes and fibroblasts with 2% chronic wound  exudate  is  shown  to  stimulate  focal  uPAR  expression[176].  In  our 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experience 2% chronic wound exudate resulted in cell death. We attempted to augment  the  known  role  of  uPAR by  treating  scratched  in‐vitro  keratinocytes with  healing  ulcer  exudates which were  known  to  have  a  significantly  higher level of suPAR compared with non‐healing ulcer exudates. Scratch coverage was better  in  healing  exudates  (1%  and  0.5%)  when  compared  with  non‐healing ulcer  exudates  (1%  and  0.5%).  Although  the  scratch  healing  potential  of  the healing  ulcer  exudates  cannot  be  completely  attributed  to  suPAR,  it  can  be concluded  that  suPAR had  an  important  role  in  the migration  and  survival  of keratinocytes  as  suggested  by  the  results  performed  in  the  presence  of Mytomicin C and suPAR‐depleted healing exudates.  
Validation of the assays could not be achieved for tissue homogenates. It may be due to the fact that the extraction buffer used may not be ideal for ulcer tissue. A number of other extraction buffers have been used[148] and attempting to use the various buffers  in order to achieve a purified extraction of uPAR may help future studies. Patients with venous ulcers may be reluctant to allow for tissue biopsies as we found during our study and due to this we did not attempt to use the small tissue samples for different types of buffers. 
The validation of suPAR for ulcer exudates was an important component of our study  and  will  help  future  work  for  detection  of  suPAR  forms  in  wound exudates.  Although  we  did  not  find  any  correlation  in  suPAR  levels  of  blood plasma  and  venous  ulcer  exudates  yet  the  validation  of  specific  antibodies  in TR‐FIAs  for  detecting  various  forms  of  suPAR  may  help  future  investigative wound studies.  
  143 
Depletion  of  suPAR  done  in  our  study  using  affinity  column  chromatography resulted in depletion of all suPAR forms. Developing an antibody that can target the suPARII‐III or suPARI  form only can help clarify  the specific roles of  these fragments  in  keratinocyte  migration  and  survival.  In  addition  PAI‐1  and vitronectin  may  influence  suPAR  functions  and  therefore  antibodies  that  can block VN and/or PAI‐1 may also elucidate the role of suPAR in ulcer healing. 
Results from this study have shown that suPAR fragments may be important in ulcer healing. The precise mechanisms by which suPAR fragments can influence healing  warrant  further  investigation.  More  importantly  what  needs  to  be determined  now  is  which  factors  influence  increased  suPAR  expression  and cleavage  within  healing  ulcers.  These  may  be  some  of  the  proteases  (MMPs) present within  venous  ulcers  but  detailed  studies  showing  the  precise  role  of such proteases resulting in increased suPAR cleavage when compared between healing and non‐healing venous ulcers is required. 
There  are  other  contributing  clinical  factors  that  impair  healing  of  a  venous ulcer  e.g  high  BMI,  poor  ankle mobility[193].  These  factors were  not  focused upon  during  this  study  but  it  would  be  prudent  to  included  these  factors  in future  studies  in  order  to  get  a  realist  influence  of  suPAR  on  venous  ulcer healing. 
The  initial  limitation  to  obtain  only  ten  blood  plasma  samples  by  the  ethics committee proved frustrating, as no meaningful outcome could be obtained for plasma  analysis.  Once  the  blood  plasma  results  were  analyzed  a  substantial amendment  was  submitted  to  the  ethics  committee  but  the  delay  in  our validation  work  meant  that  many  patients  had  already  been  started  on 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compression  therapy  by  the  time  the  first  10  plasma  samples were  analyzed. For future studies we hope there should be no limitation to the number of blood samples. 
















0  0  0  0  0 
20  5860±172  5969±436  5010±440  5504±189 
30  7078±240  7400±758  5744±506  6226±178 
60  10439±695  11197±340  8204±496  10425±725 
90  11394±258  13035±685  8678±489  11304±725 


















0  0  0  0  0  0  0  0 
40  3244±265  6389±633  5132±283  4719±367  3089±194  4838±374  5212±218 
100  2975±305  7773±742  5885±323  5043±482  2746±161  5378±499  5780±191 
200  3030±171  8686±576  5658±198  4769±383  2898±233  4301±214  5008±148 
280  3141±236  8554±786  5647±208  4736±247  2959±258  3683±220  4703±113 




















0  0  0  0  0  0  0  0  0 
40  3041±42  3736±124  3835±287  3664±12  3071±37  3303±21  3068±398  3548±102 
80  4141±38  4817±78  4530±388  4951±13  3258±19  3223±36  3656±387  3328±55 
120  5199±147  6131±156  5839±389  6250±39  3307±78  3500±12  3902±493  3569±97 
160  6566±97  7649±59  6473±527  7104±165  3131±62  4639±484  4048±578  3740±64 





WF 2.5%  WF 5%  WF 10%  WF 15%  WF 20% 
0  0  0  0  0  0 
40  5652±183  5367±382  5247±92  5104±83  5644±40 
100  7120±70  6876±288  7440±46  6763±89  6646±356 
200  7249±126  6949±401  7033±124  6210±123  5822±1141 
280  6803±121  6536±250  6122±210  5484±49  4794±1205 
360  6423±211  6092±230  5780±98  5319±73  2868±376 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